Importance: Withdrawal without a documented reason in cancer clinical trials introduces selection bias, compromises study validity, and reduces generalizability. The exclusion of this data can lead to
Data used to determine patient eligibility for cancer clinical trials often come from disparate sources that are typically maintained by different groups within an institution, use differing technolog
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid
